Skip to main content

Advertisement

SpringerLink
Log in

Prevalence of subcutaneous implantable cardioverter-defibrillator based on template ECG screening and ineligible surface ECG predicting factors in patients with hypertrophic cardiomyopathy in China

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

The subcutaneous implantable cardioverter-defibrillator (S-ICD) may provide comparable protection while avoiding the disadvantage of transvenous lead, but the abnormal features of the hypertrophic cardiomyopathy (HCM) electrocardiogram (ECG) make it a challenge for S-ICD template screening. We aimed to investigate S-ICD eligibility according to the S-ICD manufacturer’s surface ECG screening template in China, and further analyze its corresponding ineligible predicting factors in 12-lead suface ECG. A total of 179 HCM patients (114 males; mean age: 45 ± 14 years) underwent S-ICD screening at rest and on exercise, among which 91 patients (50.8%) were eligible for S-ICD. Among the patients who passed screening, 43 (47.3%) had 3 vectors eligibility; 64 (70.3%) screening qualified on both sides; 10 patients (11.0%) passed the screening while the electrodes located only on the left parasternal line versus 17 patients (18.7%) moved to the right line. The secondary sensing vector (Lead III) was mostly appropriate (53.6%), followed by the primary sensing vector (lead II, 53.1%) and the alternate sensing vector (Lead I, 46.9%). Higher R wave was the major cause, accounted for 70.5%, for screening failure. There existed significant difference in T wave in lead II, aVF, V5 and V6, adds R/T ratio in lead V5 and V6, between the screening success group (group A) and screening failure group (group B) at rest and on exercise. A multivariable logistic regression analysis was performed to identify that R/T ≤ 3.5 in lead V5 was the independent factor to predict the screening ineligibility, with odds ratio 3.648. S-ICD screening success is 50.8% in HCM patients, which is much lower than that in other studies. R/T ≤ 3.5 in lead V5 in 12-lead surface ECG was an independent predicting factor for screening failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Baudhuin LM, Kotzer KE, Kluge ML, Maleszewski JJ (2015) What is the true prevalence of hypertrophic cardiomyopathy? J Am Coll Cardiol 66(16):1845–1846

    Article  PubMed  Google Scholar 

  2. Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, Garberich RF, Udelson JE, Maron MS (2015) Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol 65(18):1915–1928

    Article  PubMed  Google Scholar 

  3. Rhyner J, Knight PB (2014) Totally subcutaneous implantable defibrillator. Cardiol Clin 32(2):225–237

    Article  PubMed  Google Scholar 

  4. Lambiase PD, Gold MR, Hood M, Boersma L, Theuns DA, Burke MC, Weiss R, Russo AM, Kaab S, Knight BP (2016) Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm 13(5):1066–1074

    Article  PubMed  Google Scholar 

  5. Maurizi N, Olivotto I, Olde Nordkamp LR, Baldini K, Fumagalli C, Brouwer TF, Knops RE, Cecchi F (2016) Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy. Heart Rhythm 13(2):457–463

    Article  PubMed  Google Scholar 

  6. Weinstock J, Bader YH, Maron MS, Rowin EJ, Link MS (2016) Subcutaneous implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy: an initial experience. J Am Heart Assoc 5(2):e002488

    Article  PubMed  PubMed Central  Google Scholar 

  7. Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J Nihoyannopoulos P, Nistri S, Pieper PG Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35(39):2733-2739.

  8. Ip JE, Wu MS, Kennel PJ, Thomas G, Liu CF, Cheung JW, Markowitz SM, Lerman BB (2017) Eligibility of pacemaker patients for subcutaneous implantable cardioverter defibrillators. J Cardiovasc Electrophysiol 28(5):544–548

    Article  PubMed  Google Scholar 

  9. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F (2000) Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 102(8):858–864

    Article  CAS  PubMed  Google Scholar 

  10. Thavikulwat AC, Tomson TT, Knight BP, Bonow RO, Choudhury L (2016) Appropriate implantable defibrillator therapy in adults with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 27(8):953–960

    Article  PubMed  Google Scholar 

  11. Maron BJ (2010) Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. Circ J 74(11):2271–2282

    Article  PubMed  Google Scholar 

  12. O'Mahony C, Lambiase PD, Quarta G, Cardona M, Calcagnino M, Tsovolas K, Al-Shaikh S, Rahman SM, Arnous S, Jones S, McKenna W, Elliott P (2011) The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart 98(2):116–125

    Article  PubMed  Google Scholar 

  13. Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ, Brady PA (2009) Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart 95(9):709–714

    Article  CAS  PubMed  Google Scholar 

  14. Olde Nordkamp LRA, Warnaars JLF, Kooiman KM, de Groot JR, Bram Rosenmoller, Wilde AAM, Knops RE (2014) Which patients are not suitable for a subcutaneous ICD: incidence and predictors of failed QRS-T-wave morphology screening. J Cardiovasc Electrophysiol 25(5):494–499

    Article  PubMed  Google Scholar 

  15. Francia P, Adduci C, Palano F, Semprini L, Serdoz A, Montesanti D, Santini D, Musumeci B, Salvati A, Volpe M, Autore C (2015) Eligibility for the subcutaneous implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrohpysiol 26(8):893–899

    Article  Google Scholar 

  16. Randles DA, Hawkins NM, Shaw M, Patwala AY, Pettit SJ, Wright DJ (2014) How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable cardioverter-defibrillator implantation? Europace 16(7):1015–1021

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We specifically thank Professor Changsheng Chen for his guidance and support mainly in statistical analysis.

Author information

Author notes

  1. Lanyan Guo, Minxia Zhang and Miaoyang Hu contributed equally to this work.

Authors and Affiliations

  1. Department of Cardiology, The First Affiliated Hospital, Fourth Military Medical University, No. 127 Changle West Road, Xi’an, 710032, Shaanxi, China

    Lanyan Guo, Minxia Zhang, Miaoyang Hu, Weiping Yang & Bing Liu

  2. Department of Ultrasound, The First Affiliated Hospital, Fourth Military Medical University, No. 127 Changle West Road, Xi’an, 710032, Shaanxi, China

    Bo Wang, Jing Wang, Lei Zuo & Liwen Liu

Authors
  1. Lanyan Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Minxia Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miaoyang Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bo Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lei Zuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Weiping Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Liwen Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Bing Liu or Liwen Liu.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, L., Zhang, M., Hu, M. et al. Prevalence of subcutaneous implantable cardioverter-defibrillator based on template ECG screening and ineligible surface ECG predicting factors in patients with hypertrophic cardiomyopathy in China. Heart Vessels 34, 851–859 (2019). https://doi.org/10.1007/s00380-018-1300-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-018-1300-8

Keywords

Search

Navigation